Authorities in Zhejiang, China granted Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) a good manufacturing practice certification for its Olgotrelvir Sodium raw material, according to a Wednesday filing with the Shanghai bourse.
Sinopep subsidiary Hangzhou Ausino Biotechnology produced the formulation, the filing said.
The drug is being used as a standalone drug for COVID-19, the National Institutes for Public Health said.